Salivary gland cancer arises in saliva-producing tissue. Benign lumps occur; tissue distinguishes cancer. Confidence: high. NCI.
- Appearance cannot establish cancer.
- Persistent lumps, facial weakness/numbness need assessment.
- AJCC 9 covers major/minor glands.
- Gland surgery can affect facial or tongue nerves.
- Slow growth can accompany late spread.
Table of contents
- Evidence summary
- Gland anatomy
- Symptoms and urgent warnings
- Risk and tumour behaviour
- Biopsy
- AJCC 9 and pathology
- Surgery
- Radiation and surgical safety
- Mouth, swallowing and nutrition
- Molecular tests/follow-up
- Human evidence and histology gaps
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
Clinical guidance and independently established outcomes have different roles. This table identifies scope and unresolved interests.
| Question | Evidence | Funding/conflicts | Limits |
|---|---|---|---|
| Diagnosis | NCI/CAP classification | Reviewer research; allocations unknown. | Distinguish benign tissue. |
| Reporting | CAP AJCC 9 | Services/research; payments unknown. | Major/minor scope. |
| Procedure roles | NCI/CUH/ESMO | Provider/author interests; trial gaps. | Nerve-specific context; no efficacy verdict. |
| Function | NCI/NHS care | Contributor/study payments unknown. | Coordinate swallowing/nutrition/follow-up. |
Gland anatomy
Major glands lie near ears, under jaw and under tongue; minor glands occur in mouth/upper airway. Lumps can be benign or malignant. NCI.
Carcinomas include mucoepidermoid, adenoid cystic, acinic cell, secretory and salivary duct types. CAP.
Keep the primary site/pathology name and report changes; do not diagnose the lump yourself.
Symptoms and urgent warnings
Changes include a lump, facial pain/weakness/numbness, difficult swallowing or limited mouth opening; some tumours are symptomless. NCI.
Sudden face drooping, arm weakness or speech problems need emergency help: UK 999 or the local emergency number, even if they stop. Do not drive or wait for a cancer appointment. NHS.
Report onset, growth and eating/facial-movement changes. Gradual weakness also needs assessment; a lump does not explain every neurological symptom.
Risk and tumour behaviour
Prior radiation is a risk factor, not proof of individual causation. Adenoid cystic carcinoma can involve nerves and recur or spread late despite slow growth. NCI.
Grade, stage, tumour genetics and general health inform planning. Grade is not a complete personal forecast; grading systems differ by cancer. NCI.
Biopsy
ESMOβs 2022 framework describes fine-needle sampling and selected core biopsy if inadequate. Major-gland open biopsy differs from experienced surgical sampling of minor-gland lesions. ESMO.
Ask what inconclusive sampling establishes.
Agree how results arrive. Discuss anaesthetic, bleeding and medicine concerns before a procedure; do not stop prescribed treatment yourself.
AJCC 9 and pathology
CAPβs April 2026 AJCC 9 protocol covers major and minor glands: histology, applicable grade, margins, nerves and nodes. Older tables do not replace it. CAP.
Stage describes cancer extent, including size and spread. NCI.
Grade describes microscopic features; it differs from stage. NCI.
Ask which edition/grade applies; interpret margins and other findings with clinicians, without a home treatment algorithm.
Surgery
Surgery/radiation roles depend on site, histology and extent. NCI.
The facial nerve passes through the parotid gland. Surgery can cause temporary or permanent facial weakness, ear numbness, saliva leakage or sweating during eating. Discuss operation-specific functional risks before consent. CUH.
Submandibular surgery can affect lower-lip movement, tongue feeling or tongue movement, temporarily or permanently. A stone/infection leaflet does not prove a cancer operationβs benefit. CUH.
Ask about removal, reconstruction, nerve preservation and postoperative contacts; a general leaflet cannot settle your cancerβs operative plan.
Radiation and surgical safety
Radiation effects depend on the field: mouth/throat problems, taste changes, skin reactions and fatigue. Effects can persist or appear later. Ask about exposed tissues, prevention, monitoring and contacts. NCI.
Operations can cause bleeding, infection, pain, nearby-tissue injury or anaesthetic reactions. Obtain preparation and urgent-contact instructions; report uncontrolled pain or concerning wound changes. NCI.
Ask about cure, control or symptom relief.
Check current histology-specific approvals locally; a 2022 guideline or squamous-cancer list cannot supply them.
Mouth, swallowing and nutrition
Treatment can cause dryness, soreness, infection, taste changes or dental problems. Coordinate dental care with oncology; report pain impairing eating or sleep. NCI.
Ask the oncology and dental teams before invasive dental work; no home rinse prescription is given.
Coughing/choking with intake, sticking food, a wet voice or breathlessness after meals needs urgent GP advice or UK NHS 111; use the local urgent service elsewhere. Dysphagia can cause dehydration, weight loss or chest infection. NHS.
Severe breathing difficulty, gasping/choking, inability to get words out, colour change or sudden confusion needs UK 999/A&E or local emergency help. Do not drive. NHS.
Rehabilitation may involve speech, swallowing, dental or reconstructive care. Include function in planning. NCI.
Report weight, intake and communication changes. Ask about nutrition and speech-language support; assessment must guide food texture, fluid volume or feeding route, not an automatic thickener or supplement drink.
Molecular tests/follow-up
Selected histologies prompt androgen receptor, HER2 or NTRK-fusion testing. Historical testing guidance does not establish current drug eligibility or benefit for every alteration. ESMO.
No diet, herb or supplement is proved to cure cancer or prevent return. Products can alter cancer-medicine effects; show ingredients to a pharmacist before adding extracts or high-dose vitamins. Documented deficiency is a separate clinical question. NCI.
Keep pathology and treatment records, follow-up responsibility and changes to report. Share these with primary and dental care. Monitoring is individual; no scan interval or stopping rule is provided. NCI.
Clarify a molecular result before buying a test or treatment.
Human evidence and histology gaps
Trials can study tumour treatment or supportive care. Ask about comparators, patient outcomes, harms, costs and funders. Experimental care promises no benefit; animal/cell results cannot establish safe human treatment. NCI.
Manufacturer-funded or supplied-product outcomes are excluded from an independent efficacy verdict. Public agencies, editorial review and guidelines do not clear underlying trials. Financial gaps remain visible.
Detailed care for adenoid cystic, mucoepidermoid, acinic cell, secretory, salivary duct and carcinoma ex pleomorphic adenoma remains unassessed. Lymphoma, melanoma and sarcoma need separate frameworks.
For a second opinion, send the original report and ask whether slides or scans are needed. Ask what uncertainty affects the decision; this guide supplies no personal staging, medicine, radiation or surgery regimen.
Funding and source roles
Research funding at a glance
36 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this articleβs source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
Shared-route pointers identify institutional profiles; exact page/author/trial allocations remain unknown. Public or academic branding does not establish independent efficacy.
| Source | Funding/backers | Country/jurisdiction | Independence | Credibility/incentives/gaps |
|---|---|---|---|---|
| NCI professional PDQ | Policy; Bonetti supply; Truong. Payments unknown. | US; international reviewers. | Tier 3 | C, provisional. Trials unclosed. |
| NCI patient PDQ | Professional derivation; same reviewer/payment gaps. | US. | Tier 3 | C, provisional. |
| CAP 2026 protocol | Revenue; Cipriani research. Protocol/other-author payments unknown. | US; contact. | Tier 3 | C, provisional. |
| ESMO 2022 guideline | ESMO funds/paid editing; no external guideline funds reported. Author interests: Atos Medical/BMS/Merck/MSD/Sanofi/Lilly/others; payments/backer jurisdictions unclosed. | Via Ginevra 4, Lugano, Switzerland. | Tier 3 | C, provisional; dated. |
| ESMO 2023 accounts | Meeting/education, membership, grants, investment/other income; pharmaceutical supporters. Finance May 2022βApril 2023; supporters September 2022βJuly 2023. Current ledger unclosed. | Switzerland; guideline address. | Tier 3 | B, provisional. |
| CUH parotid leaflet | Provider finances; leaflet/author/study allocations unknown. | Hills Road, Cambridge, UK. | Tier 2 | B, provisional. |
| CUH submandibular leaflet | Provider finances; same unclosed allocations. | Hills Road, Cambridge, UK. | Tier 2 | B, provisional. |
| CUH 2025β26 accounts | Notes 2.1β2.3: NHS England/ICB care, private/overseas patients, R&D, training, services, rents, capital donations; industry, NIHR/charity research. No leaflet allocation. | Cambridge, UK; own executive contact. | Tier 3 | B, provisional; service/research incentives, full author/page chains unclosed. |
| Surgery | NCI/gift routes; allocations unknown. | US. | Tier 2 | B, provisional. |
| NHS stroke | National policy; author/study payments unknown. | UK. | Tier 2 | B, provisional. |
| 2023 corrigendum | Companion interests; amendment money unknown. | Switzerland; companion address. | Tier 3 | C, provisional. |
| Staging | NCI/gift routes; allocations unknown. | US. | Tier 2 | B, provisional. |
| Grade | NCI/gift routes; allocations unknown. | US. | Tier 2 | B, provisional. |
| CAP releases | Revenue; release/contributor allocations unknown. | US; contact. | Tier 3 | B, provisional; identity only. |
| CAP 2025 finances | Testing, accreditation, publications, membership, education, sponsorship/advertising, investments/other revenue. Protocol allocations/full audited ledger unknown. | US; contact. | Tier 3 | B, provisional; service/advocacy incentives. |
| CAP contact | Mixed revenue; author/study chains unknown. | 325 Waukegan Road, Northfield, Illinois; Washington office, US. | Tier 3 | B, provisional; identity only. |
| DEPEND 2025 finance | Nicole A. Cipriani interpretation/review; BMS/Celgene funding and Chicago P30 CA14599. BMS manuscript review. No other Cipriani disclosure reported; not personal/protocol payment. | Chicago, US. Sponsor ownership/HQ/contracts/income unclosed. | Tier 4 | D; seller-funded. Finance only; efficacy excluded. |
| Head/neck rehabilitation | NCI/gift routes; allocations unknown. | US. | Tier 2 | B, provisional. |
| Mouth/throat | NCI/gift routes; allocations unknown. | US. | Tier 2 | C, provisional. |
| Radiation | NCI/gift routes; allocations unknown. | US. | Tier 2 | B, provisional. |
| Diets/supplements | NCI/gift routes; allocations unknown. | US. | Tier 2 | B, provisional. |
| Follow-up | NCI/gift routes; allocations unknown. | US. | Tier 2 | B, provisional. |
| Trials | NCI/gift routes; allocations unknown. | US. | Tier 2 | B, provisional. |
| NHS swallowing | National policy; author/study payments unknown. | UK. | Tier 2 | C, provisional. |
| NHS breathing | National policy; author/study payments unknown. | UK. | Tier 2 | B, provisional. |
| Andrea Bonetti biography | PDQ member; Pederzoli trial/accreditation consultancy since 2024; EORTC 2129 responsibility. Remuneration/PDQ allocation unknown. | Italy; Pederzoli consultancy, former Mater Salutis/Legnago role. Income/beneficial ownership unclosed. | Tier 3 | C, provisional; identity/research self-report, remuneration unclosed. |
| EORTC/Menarini supply | October 19, 2023: Menarini/wholly-owned Stemline provide elacestrant for EORTC 2129. Bonetti role separately documented; no personal/PDQ fee inference. | Brussels/Florence dateline; contracts/assay support/manufacturing jurisdictions unclosed. | Tier 4 | D; supplied-product research. Finance only; efficacy excluded. |
| EORTC finances | Institutional/corporate/private donations; study/service fees; industry trials; EU and restricted/unrestricted grants. No direct government subsidy. Chart/narrative periods differ; full current ledger unclosed. | Belgian law; Brussels contact. | Tier 3 | B, provisional; fundraising, project/reviewer allocation gaps. |
| EORTC contact | Mixed revenues; trial-site map unknown. | Avenue Emmanuel Mounier 83/11, 1200 Brussels, Belgium. | Tier 3 | B, provisional; identity only. |
| Menarini identity | A. Menarini Industrie Farmaceutiche Riunite SRL; Florence registration. Supply route. Beneficial ownership, amounts, remuneration, subcontractors unclosed. | Via Sette Santi 1, 50131 Firenze, Italy; factories unclosed. | Tier 4 | D; supplier self-report, identity only. |
| Minh Tam Truong ASTRO 2024 | BMC/Boston University employment; no ownership/leadership. Compensation field is a malformed placeholder, not no income. Full revenues/backer jurisdictions/PDQ payments unclosed. | Boston, Massachusetts, US. | Tier 3 | C, provisional; incomplete self-report. |
| ASTRO 2022 disclosures | Truong BMC/VA roles and ABR travel; previous-year/activity scope. Other facultyβs interests not assigned to her. ASTRO/ABR revenue, travel amounts, current income unclosed. | Boston affiliations, US. | Tier 3 | B, provisional; historical self-report, not 2025 page payment. |
| NCI budget | Congress through HHS/NIH; enacted/requested funds differ. Page allocations unknown. | US federal agency. | Tier 3 | B, provisional; institutional priorities. |
| NCI contributions | Public gifts/Gift Fund/Breast Cancer Research Stamp, separate from Congress. Named donors/receipts/page payments unclosed. | Contribution address: 9000 Rockville Pike, Bethesda, Maryland, US. | Tier 3 | B, provisional; fundraising self-report. |
| PDQ board policy | NCI support; nongovernment members receive honoraria/travel/lodging. Declarations/recusal; specific conflicts not publicly required. Member/trial interests unclosed. | US; international contributors. | Tier 3 | B, provisional; process only. |
| NHS content policy | DHSC; no ads/corporate sponsorship reported. Page/expert receipts unknown. | UK national website, not provider finance. | Tier 3 | B, provisional; October 2025 review overdue. |
Frequently asked questions
Does a gland lump mean cancer? No; it can be benign. NCI.
Is slow-growing adenoid cystic cancer harmless? No; late spread can occur. NCI.
Major/minor carcinoma framework? April 2026 AJCC 9 protocol. CAP.
Can gland surgery affect movement or feeling? Yes; risk depends on gland and operation. Parotid; submandibular.
Sources and funding notes
May 2025 lead attribution: NCI.
March 2025 patient derivation reviewed. NCI.
April 2026 selected protocol reviewed. CAP.
2022 biopsy/molecular context and complete declarations: ESMO original.
Selected 2023 finance remains historical. ESMO.
Corrigendum amendment text read through Amsterdam UMC; fresh PDF access unavailable. Exact protocols/outcomes excluded.
Selected 2025β26 provider notes reviewed; leaflet approvals July 2025. CUH.
Numerical prognosis, personal regimens, complete current drug menus and sponsored efficacy are excluded. Detailed histology treatment and complete contributor/trial/page finances remain unassessed.
- NCI professional PDQ β May 13, 2025; selected roles.
- NCI patient PDQ β March 14, 2025; selected anatomy/symptoms.
- CAP 2026 protocol β April 2026; selected current classification.
- ESMO 2022 guideline β Selected biopsy/molecular context; full declarations.
- ESMO 2023 accounts β Historical selected finances.
- CUH parotid leaflet β July 29, 2025; selected risks.
- CUH submandibular leaflet β July 18, 2025; selected risks.
- CUH 2025β26 accounts β Actual 197-page original, selected notes/research/contact.
- Surgery β November 8, 2024; operative safety.
- NHS stroke β September 12, 2024; emergency distinction.
- 2023 corrigendum β Amendment text via university record; protocols/outcomes excluded.
- Staging β October 14, 2022; extent.
- Grade β August 1, 2022; microscopy.
- CAP releases β Selected April 2026 entries.
- CAP 2025 finances β Selected own financial tables.
- CAP contact β Own address.
- DEPEND 2025 finance β March 6, 2025; actual role/declarations.
- Head/neck rehabilitation β May 25, 2021; selected function.
- Mouth/throat β September 24, 2021; selected harms.
- Radiation β May 15, 2025; field/late effects.
- Diets/supplements β October 30, 2024; cure/interaction boundaries.
- Follow-up β Selected individualized care.
- Trials β November 3, 2024; research categories.
- NHS swallowing β May 2, 2023; review overdue.
- NHS breathing β January 30, 2024; emergency distinction.
- Andrea Bonetti biography β Current own biography; update-date gap.
- EORTC/Menarini supply β Dated joint announcement.
- EORTC finances β Own institutional model.
- EORTC contact β Own address.
- Menarini identity β Own current company/contact.
- Minh Tam Truong ASTRO 2024 β Entire visible declaration; no treatment claims.
- ASTRO 2022 disclosures β Actual three-page original.
- NCI budget β May 14, 2026; own budget.
- NCI contributions β August 2025; routes/contact, not sole headquarters.
- PDQ board policy β November 1, 2022; own policy.
- NHS content policy β October 14, 2022; own policy.
Educational research reviewed 5 October 2026. Diagnosis and treatment require a qualified clinician; this article supplies no individual prescription and does not replace urgent assessment.
Have a question β or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.